2 Underrated Weight Loss Stocks to Buy and Hold
They look well-positioned to grab a slice of the fast-growing anti-obesity market.
2 Underrated Weight Loss Stocks to Buy and Hold
Overview
Investors interested in weight-loss stocks may naturally gravitate toward Eli Lilly and Novo Nordisk. That makes sense. They are currently the leaders in this niche. Their brands, Zepbound and especially Wegovy, have practically become household names and are synonymous with chronic weight management. However, many other drugmakers could capitalize on the soaring demand for weight loss medicines. Two of the most promising to consider right now are Regeneron (NASDAQ: REGN) and Amgen (NASDAQ: AMGN). Here is why these companies are worth a second look for investors seeking exciting weight-loss stocks.
Image source: The Motley Fool.
Regeneron plans to start phase 3 clinical trials for one of its leading weight-loss candidates, olatorepatide, sometime this year. This medicine mimics the action of two separate gut hormones: GLP-1 and GIP, just like Zepbound does. What's more, olatorepatide has already posted solid late-stage clinical trial results in China. In a 48-week study enrolling 604 patients, the medicine led to weight loss of up to 19% among participants.
Details
Source
Originally published at www.fool.com.
